M
MedgenLife Science
Company News2024-01-311 min read

Medgen's Major Science and Technology Project Receives Shenzhen Government Funding

By Medgen Life Science

Major Project Approved

The Shenzhen Science and Technology Innovation Commission recently issued its notice on funded science and technology projects. Medgen's major science and technology project — "Key Technologies for Composite Materials for Artificial Tendons" — was successfully approved for project funding.

This project is the first to use non-degradable materials as a matrix while successfully introducing specific bioactive molecules that enable the material surface to interact with cell surface receptors, activate cell signaling pathways, and significantly promote cell ingrowth — effectively addressing a critical clinical bottleneck.

Innovation-Driven

Medgen has always been firmly committed to innovation as its driving force, continuously increasing R&D investment and achieving a series of original research outcomes through persistent exploration. This project stood out in fierce competition among numerous universities and research institutions, earning project approval and fully demonstrating the company's R&D strength and innovative capability while highlighting the core competitiveness of its original research programs.

The achievements to date not only hold a leading advantage at the technological level but also show tremendous value potential for the future. Medgen will continue to increase R&D investment, providing stronger support for the transformation and application of medical devices in clinical practice.

Related Articles

After 8 years of independent R&D, Medgen Life Science's three core products — BoneSwift™ injectable bone graft, PoroGraft® oral bone filler, and PRP preparation device — have all received NMPA Class III medical device certification, with multiple technologies filling domestic market gaps.

3 min readRead More
All Articles